Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-02-21
2006-02-21
Spector, Lorraine (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C530S350000
Reexamination Certificate
active
07001599
ABSTRACT:
2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation.
REFERENCES:
patent: 5488032 (1996-01-01), Dower et al.
patent: 6451760 (2002-09-01), Parnet et al.
Buckler et al. Two-step stimulation of B lymphocytes to enter DNA synthesis: synergy between anti-immunoglobulin antibody and cytochalasin on expression of c-myc and a GI-specific gene. Mol Cell Biol. Mar. 1988;8(3):1371-5 (abstract only).
Torigoe et al. Purification and Characterization of the Human Interteukin-18 Receptor. Vol. 272, No 41, Issue of Oct. 10, 1997 pp. 25737-25742.
Norbert W. Tietz, Ph.D., “7-Lipids, Lipoproteins, and Apolipoproteins,”Textbook of Clinical Chemistryp. 842.
Isselbacher er al., “Eicosanoids and Human Disease,”Harrison's Principles of Internal Medicine,1(13):433-435.
Baum et al., “Molecular characterizastion of murine and human 0X40/0X40 ligand systems: identification of a human 0X40 ligand as the HTLV-l-regulated protein gp34,”The EMBO Journal, 13(1 7):3992-4001, 1994.
Bergers et al, “Alternative promoter usage of the Fos-responsive gene Fit-1 generated mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor,”EMBO Journal, 13(5):1176-1188, 1994.
Hashimoto et al., “TheTollGene of Drosophila, Required for Dorsal-Ventral Embryonic Polarity, Appears to Encode a Transmembrane Protein,”Cell, 52:269-27, Jan. 29, 1988.
Arend et al., “Binding of IL-α, I-1L-β, and IL-1 Receptor Antagonist by Soluble IL-1 Receptors and Levels of Soluble IL-1 Receptors in Synovial Fluids,”The Journal of Immunology, 153(10):4767-4774, Nov. 15, 1994.
Jean Marx, “How the Glucocorticoids Suppress Immunity”Science, 270:232-233, Oct. 13, 1995.
Auphan et al., “Immunosuppression by Glucocorticoids: Inhibition of NF-kB Activity Through Induction of 11kB Synthesis,”Science, 270:286-290, Oct. 13, 1995.
Howard et al., “Soluble tumor necrosis factor receptor: Inhibition of human immunodeficiency virus activation,”Proc. Natl. Acad. Sci. USA. p. 2335, Mar. 1993.
Yamamoto et al., “Transcriptional Roles of Nuclear Factor kB and Nuclear Factor-Interleukin-6 inthe Tumor Necrosis Factor α-Dependent Induction of Cyclooxygenase-2 in MC3T3-E1 Cells,”The Journal of Biological Chemistry, 270(52):31315-31320, 1995.
Weih et al., “Multiorgan Inflaxnmation and Hematopoietic Abnormalities in Mice with a Targeted Disruption of ReIB, a Member of the NF-kB/Rel Family Cell,”80:331-340, January 27, 1995.
Sha et al., “Targeted Disruption of the p50 Subunit of NF-kB Leads to Multifocal Defects in Immune Responses,”Cell, 80:321-330, January 27, 1995.
Thanos et al., NF-kB: A Lesson in Family ValuesCell, 80:529-532, Feb. 24, 1995.
Carter et al., “Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein,”Nature, 344:633-637, Apr 12, 1990.
Nomura et al., Prediction of the Coding Sequencesof Unidentified Human Genes. I. The Coding Sequences of 40 New Genes (KLAA0001-KLAA0040) Deduced by Analysis of Randomly Sampled cDNA Clones from Human Immature Myeloid Cell Line KG-1,DNA Research, 1:27-35, 1994.
Lord et al., “Nucleotide sequence and expression of a-cDNA encoding MyD88, a novel myeloid differentiation primary response gene induced by IL6,”Oncogene, 5(7):1095-1097, Jul. 1990.
Greenfeder et al.,“Molecular Cloning and Characterization of a Second Subunit of the Interleukin I Receptor Complex,”The Journal of Biological Chemistry, 270(23): 13757-13765, 1995.
Sims et al., “Geonomic Organization of the Type I and Type II IL-1 Receptors,”Cytokine, 7(6):483-490, Aug. 1995.
Price et al., “Pathophysiology Clinical Concepts of Disease Processes,” p. 36-38, 1986.
Crowell et al., “Functional Bowel Disorders and Dysmenorrhea: Don't Cramp My Style,”Gastroenterology, 109(3):1017-1019, Sep. 1995.
Charles A. Dinarello, “Interleukin-1 and Its Biologically Related Cytokines,”Advances in Immunology, 44:153-205, 1989.
William P. Arend, “Interleukin-1 Receptor Antagonist,”Advances in Immunology, 54:167-227, Jan. 19, 1993.
Parnet et al., “A Novel Receptor Similar to the Type I Interleukin I Receptor and T1/ST2,” Poster presented at Lake George, NY, Oct. 1995.
Rosenberg et al., Immunopathogenesis of HIV Infection,FASEB Journal. 5: p. 2384, Jul. 1991.
Anthony S. Fauci, :Multifactorial Nature of Human Immunodeficiency Virus Disease: Implications for Therapy,Science, 262:1011-1014; Nov. 12, 1993.
Torigoe K., et al., “Purification and characterization of the human interleukin-18 receptor,”Biol Chem272(41):25737-25742, 1997.
Novick D., et al., “Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response,”Immunity10(1): 127-136, 1999.
Parnet P., et al., “IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologucs T1/ST2 and IL-1R AcP,”J. Biol Chem271(8):3967-3970, 1996.
Reznikov LL, et al., “IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-g,”Proc. Natl. Sci., 97(5):3174-2179, 2000.
Dinarello CA, “Targeting interleukin 18 with interleukin 18 binding protein,”Ann. Rheum. Dis., 59 Suppl.: i17-20, 2000.
Dinarello CA,“Interleukin-18, a proinflammatory cytokine,”Eur. Cytokine Netw. 11(3):483-486.
J.S. Sandhu, Protein engineering of antibodies. 1992, Critical Reviews in Biotech, 12(5/6): 437-462. Copy was sent on Feb. 8, 2005.
Parnet Patricia
Sims John E.
Henry Janis C.
Immunex Corporation
Jiang Dong
Spector Lorraine
LandOfFree
Methods for treating inflammation with 2F1 antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating inflammation with 2F1 antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating inflammation with 2F1 antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3655800